MiNK Therapeutics, Inc.
NASDAQ:INKTBiotechnology
-$0.35 today
- Market cap
- $52.17M
- Beta
- 0.47
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$2.60
Volume 0.01M
Average 0.05M
INKT Net Income
Bottom-line profit, the starting point for calculating cash from operations.
MiNK Therapeutics, Inc.NASDAQ: INKT
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income dips below year-ago levels
Q1 FY2026 net income of $2.74M (cash outflow) fell 0.9% year over year, behind the +128201.2% change in trailing-twelve-month net income. Sequentially, it fell 100.0% from the prior quarter. Over 3 fiscal years it compounded at -23.6% a year.
Context
- Net income grew in size in 1 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 2 analysts of -$11.9M (-4.8%) for the fiscal year ending Dec 2026, a slowdown from the +15.9% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$2.74M-100.0% QoQ
- Last fiscal yearDec 2025
- -$12.49M+15.9% YoY
- LTMMar 2026
- -$12.49B+128201.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -0.9% | -32.1% | -31.2 pp |
| 1 year | +15.9% | -4.8% | -20.6 pp |
| 3-year CAGR | -23.6% | +6.1% | +29.6 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (12.49M) USD
- Year-over-year change
- -15.9%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (12.49M) | -15.9% |
| FY2024 | 2024-12-31 | (10.78M) | +52.0% |
| FY2023 | 2023-12-31 | (22.46M) | +19.8% |
| FY2022 | 2022-12-31 | (27.99M) | +7.4% |
| FY2021 | 2021-12-31 | (30.21M) | — |
Net Income vs competitors
How INKT compares with its peers on the latest reported figures
- INKT's LTM Mar 2026 net income of $12.49B is the 2nd largest of the 9 companies compared; the peer median is $29.58M.
- Its year-over-year change of +128201.2% is the 2nd highest of 9, against a peer median of +1.6%.
- Over three fiscal years its annual growth of -23.6% compares with a peer median of +1.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
OSTXOS Therapies Incorporated | LTM Mar 2026 | $28.76B | +254398.4% | +1562.8% | — |
| LTM Mar 2026 | $12.49B | +128201.2% | -23.6% | — | |
| LTM Mar 2026 | $60.96M | -388.6% | -1.9% | 18297.5% | |
| LTM Mar 2026 | $37.19M | -32.9% | -5.5% | — | |
| LTM Jun 2026 | $34.61M | -52.7% | +4.2% | 164.8% | |
| LTM Mar 2026 | $24.54M | +1.8% | -10.4% | 1070.2% | |
| LTM Mar 2026 | $21.24M | +1.5% | +4.7% | — | |
| LTM Mar 2026 | $19.06M | +36.2% | -28.9% | — | |
| LTM Mar 2026 | $918K | +104.2% | +17.5% | 2.5% | |
| Peer median (excluding INKT) | $29.58M | +1.6% | +1.2% | 617.5% | |
Competitors are the stored peer set for INKT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (30.21M) | (27.99M) | (22.46M) | (10.78M) | (12.49M) |
| Depreciation & Amortization | 77.96K | 121.75K | 204.62K | 215.44K | 181.75K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.74M | 3.03M | 3.86M | 1.81M | 2.67M |
| Change in Working Capital | 3.74M | 8.77M | 2.9M | 459.73K | 3.29M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (152.04K) | 2.66M | (1.92M) | (1.18M) | 689.71K |
| Other Working Capital | 3.89M | 6.11M | 4.81M | 1.64M | 2.6M |
| Other Non-Cash Items | 11.83M | (2.79M) | (266.78K) | (1.26M) | 424.63K |
| Operating Cash Flow | (12.83M) | (18.87M) | (15.76M) | (9.56M) | (5.93M) |
| Capital Expenditures | (248.98K) | (250.05K) | (73.56K) | (4) | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (248.98K) | (250.05K) | (73.56K) | 0 | 0 |
| Debt Repayment | 9.46M | 0 | 0 | 5M | 0 |
| Common Stock Issued | 39.8M | 0 | 0 | 5.8M | 14.9M |
| Common Stock Repurchased | 0 | (157.19K) | (477.64K) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 150 | 1.6K | 70.47K | 19.99K | (173.35K) |
| Financing Cash Flow | 49.26M | (155.6K) | (407.17K) | 10.82M | 14.72M |
| Effect of Forex Changes | 16.9K | 19.39K | (25.25K) | (54.7K) | (13.43K) |
| Net Change in Cash | 36.2M | (19.25M) | (16.27M) | 1.21M | 8.78M |
| Free Cash Flow | (13.08M) | (19.12M) | (15.84M) | (9.56M) | (5.93M) |
MiNK Therapeutics, Inc.
NASDAQ:INKT
Intrinsic Alpha fair value
Locked
Current Price
$10.22
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.